Loading…
Heron Therapeutics, Inc. is projected to decline to $0.3824 by 2027, a -8% move from its current price of $0.4144. HRTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.3981 | $0.4141 | $0.4308 | -0.07% |
| Jul 14 | $0.3914 | $0.4138 | $0.4375 | -0.14% |
| Jul 15 | $0.3862 | $0.4135 | $0.4427 | -0.21% |
| Jul 16 | $0.3819 | $0.4132 | $0.4471 | -0.28% |
| Jul 17 | $0.3781 | $0.4129 | $0.451 | -0.35% |
| Jul 18 | $0.3747 | $0.4127 | $0.4545 | -0.42% |
| Jul 19 | $0.3715 | $0.4124 | $0.4577 | -0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3715 | $0.4124 | $0.4577 | -0.49% |
| Week 2 | $0.3541 | $0.4103 | $0.4755 | -0.98% |
| Week 3 | $0.3408 | $0.4083 | $0.4892 | -1.47% |
| Week 4 | $0.3298 | $0.4063 | $0.5005 | -1.95% |
| Week 5 | $0.3202 | $0.4043 | $0.5105 | -2.43% |
| Week 6 | $0.3116 | $0.4023 | $0.5194 | -2.91% |
| Week 7 | $0.3038 | $0.4003 | $0.5276 | -3.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company that develops and commercializes therapies. It uses its proprietary Biochronomer technology to deliver therapeutic levels of short-acting pharmacological agents over a period from days to weeks with a single administration.
The company offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Heron is developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc.
and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Heron Therapeutics, Inc. (HRTX) operates in the Healthcare sector as a biotechnology company focused on therapeutic development and commercial products. It currently trades with a price of $0.4175 per share and a market capitalization of $79.02M, and it ranks 4359 by market cap.
The near-term technical picture is neutral, with RSI at 20 and price action below key moving averages. The stock’s current price is supported by a defined level at $0.38 and faces resistance at $1.31 as part of its price discovery path.
The stock displays a 30-day range from $0.3019 to $0.5775, with an annualized volatility of 90%, indicating high price fluctuations and sensitivity to market movements.
A major floor 87.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 114.8% above — a clean break opens room to run.
A major ceiling 216.1% above — clearing it would confirm fresh momentum.
Key HRTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HRTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.43 | Sell | $0.4264 | Sell |
| MA 10 | $0.431 | Sell | $0.4294 | Sell |
| MA 20 | $0.42 | Sell | $0.4599 | Sell |
| MA 50 | $0.692 | Sell | $0.615 | Sell |
| MA 100 | $0.8322 | Sell | $0.7945 | Sell |
| MA 200 | $1.05 | Sell | $1.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.46 | Neutral |
| Stoch RSI (14) | 52.65 | Neutral |
| CCI (20) | -47.62 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -2.38 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.07 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 39.62 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 0.43 | Sell |
| ADX (14) | 35.90 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL. RSI14: 20. SMA50: $0.8622. SMA200: $1.11.
Support: $0.38. Resistance: $1.31.
30-day range: $0.3019 to $0.5775. Annualized volatility: 90%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.38 | $0.4144 | $0.4553 | 0% | Neutral | |
| $0.2919 | $0.3824 | $0.5368 | -8% | Neutral | |
| $0.2806 | $0.3834 | $0.566 | -7% | Neutral | |
| $0.3159 | $0.4473 | $0.6864 | +8% | Neutral | |
| $0.3587 | $0.5243 | $0.831 | +27% | Bullish | |
| $0.3448 | $0.5189 | $0.8458 | +25% | Bullish | |
| $0.3475 | $0.5376 | $0.8984 | +30% | Bullish | |
| $0.3254 | $0.5168 | $0.8832 | +25% | Bullish | |
| $0.2956 | $0.4812 | $0.8396 | +16% | Neutral | |
| $0.314 | $0.5237 | $0.9312 | +26% | Bullish | |
| $0.4156 | $0.7758 | $1.49 | +87% | Bullish | |
| $0.5592 | $1.24 | $2.68 | +200% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.38 | $0.4144 | $0.5009 | +0.00% |
| August 2026 | $0.3312 | $0.3956 | $0.4885 | -4.53% |
| September 2026 | $0.3221 | $0.3886 | $0.4875 | -1.77% |
| October 2026 | $0.3227 | $0.3929 | $0.4994 | +1.10% |
| November 2026 | $0.3052 | $0.3743 | $0.481 | -4.73% |
| December 2026 | $0.2839 | $0.3507 | $0.4553 | -6.30% |
Click any year to see its month-by-month HRTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Heron Therapeutics, Inc.'s 2026 outlook centres on $0.4144, within a $0.38 to $0.4553 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, HRTX could reach as high as $0.5368, with a base case around $0.3824 and support toward $0.2919 — roughly -8% from $0.4144. Price action looks broadly range-bound.
Expect HRTX to range from $0.2806 to $0.566 through 2028. The $0.3834 average target implies a -7% move from current prices. That is up 0% on the projected 2027 average. A consolidation phase looks the most probable path here.
The HRTX price prediction for 2029 points to an average of $0.4473 (low $0.3159, high $0.6864) — a potential gain of +8% on today's $0.4144. Price action looks broadly range-bound.
In 2030, HRTX is projected to trade between $0.3587 and $0.831, averaging $0.5243 — a potential gain of +27% from today's $0.4144. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Heron Therapeutics, Inc.'s 2031 outlook centres on $0.5189, within a $0.3448 to $0.8458 range. That is -1% versus the projected 2030 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2032, HRTX could reach as high as $0.8984, with a base case around $0.5376 and support toward $0.3475 — roughly +30% from $0.4144. Buyers look set to stay in control over this stretch.
Expect HRTX to range from $0.3254 to $0.8832 through 2033. The $0.5168 average target implies a +25% move from current prices. That is -4% versus the projected 2032 average. Momentum favours further upside here.
The HRTX price prediction for 2034 points to an average of $0.4812 (low $0.2956, high $0.8396) — a potential gain of +16% on today's $0.4144. A consolidation phase looks the most probable path here.
In 2035, HRTX is projected to trade between $0.314 and $0.9312, averaging $0.5237 — a potential gain of +26% from today's $0.4144. That is up +9% on the projected 2034 average. Momentum favours further upside here.
Heron Therapeutics, Inc.'s 2040 outlook centres on $0.7758, within a $0.4156 to $1.49 range. That is up +48% on the projected 2035 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, HRTX could reach as high as $2.68, with a base case around $1.24 and support toward $0.5592 — roughly +200% from $0.4144. Momentum favours further upside here.
Investing $1,000 in HRTX today (≈ 2,413.127413 HRTX) could be worth
$2,998.49
+$1,998.49 (+200%) by 2050 · US Dollar
Based on the average projected HRTX price of $1.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HRTXwould be worth at today's price.
$1,000 invested in HRTX on Jul 10, 2025 (≈ 450.450445 HRTX) would be worth
$186.67
-$813.33 (-81.3%) today · 0.19× · US Dollar
Based on a HRTX entry price of $2.22 vs. today's $0.4144.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.44 | $941.82 | -5.8% |
| 1 month ago | $0.41 | $1,010.73 | +1.1% |
| 3 months ago | $0.85 | $487.53 | -51.2% |
| 6 months ago | $1.49 | $278.12 | -72.2% |
| 1 year ago | $2.22 | $186.67 | -81.3% |
| All time (5.0y) ago | $13.48 | $30.74 | -96.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HRTX forecast.
Our base-case forecast reaches $0.83 around 2050.
Implied market cap at $0.83: $157.1M
The multi-year forecast shows a choppy to gradually upward path with varying sentiment across years. In 2026, the average price is $0.4175 with min $0.38 and max $0.4558, and ROI 0, sentiment NEUTRAL. The sequence includes 2027 with min $0.2786, avg $0.3795, max $0.5581, ROI -9.1, sentiment NEUTRAL, and 2028 with min $0.2391, avg $0.3439, max $0.5363, ROI -17.6, sentiment BEARISH.
From 2029 onward, the outlook turns modestly more constructive, with 2029 min $0.2807, avg $0.423, max $0.6901, ROI 1.3, sentiment NEUTRAL; 2030 min $0.332, avg $0.5218, max $0.8839, ROI 25, sentiment BULLISH; 2031 min $0.2983, avg $0.4875, max $0.8532, ROI 16.8, sentiment NEUTRAL; 2032 min $0.3091, avg $0.5244, max $0.9445, ROI 25.6, sentiment BULLISH. The 2040 forecast shows min $0.3096, avg $0.6855, max $1.45, ROI 64.2, sentiment BULLISH; and 2050 shows min $0.5058, avg $1.12, max $2.59, ROI 169.2, sentiment BULLISH.
These are estimates, not guarantees, and reflect probabilistic paths for the asset over the stated horizons.
Tap a question to reveal the answer.
2030 forecast: min $0.332, avg $0.5218, max $0.8839; ROI 25; sentiment BULLISH.
The forecast shows mixed signals: early years are neutral or bearish (e.g., 2027/2028), with stronger upside expected in 2030, 2040 and 2050. Current price is $0.4175 and market cap $79.02M, indicating notable volatility and risk.
Yes, the forecast shows a 2040 max of $1.45 and a 2050 max of $2.59, indicating potential upside beyond $1 over the longer horizon.
Current price: $0.4175. Market cap: $79.02M.
2040: min $0.3096, avg $0.6855, max $1.45; ROI 64.2; sentiment BULLISH.
Heron Therapeutics, Inc. Community Discussion
0Share your Heron Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.